Literature DB >> 26286909

Cardiac devices with class 1C antiarrhythmics: a potentially toxic combination.

Andrew Apps1, Charles Philip Miller2, Sarah Fellows1, Michael Jones3.   

Abstract

A patient taking regular flecainide for paroxysmal atrial fibrillation presented with broad complex tachycardia and circulatory compromise. With no history of pacemaker insertion and no pacing spikes visible on the ECG, this was presumed to be ventricular tachycardia and treated with electrical cardioversion, leading to p-wave asystole. An indwelling pacemaker was now recognised and ventricular capture was eventually attained by significantly increasing ventricular lead output. Invasive haemodynamic support was required due to new ventricular systolic dysfunction. Pacing thresholds and ventricular function normalised within 72 h consistent with flecainide toxicity; levels were shown to be toxic. Pacemaker interrogation revealed evidence of an undiagnosed atrial flutter, at presentation this was likely slowed by flecainide toxicity to a rate below the pacemaker mode switch, such that it was tracked in the ventricle at the upper tracking rate (120 bpm). Cardioversion terminated the arrhythmia but raised the capture threshold of the ventricle above the maximum lead output. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26286909      PMCID: PMC4550908          DOI: 10.1136/bcr-2015-210598

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Assessing the excitable gap in reentry by resetting. Implications for tachycardia termination by premature stimuli and antiarrhythmic drugs.

Authors:  H Fei; M S Hanna; L H Frame
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

2.  Successful extracorporeal life support in a case of severe flecainide intoxication.

Authors:  G M Auzinger; C D Scheinkestel
Journal:  Crit Care Med       Date:  2001-04       Impact factor: 7.598

3.  Life-threatening flecainide toxicity. A pharmacodynamic approach.

Authors:  B R Winkelmann; H Leinberger
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

4.  Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing thresholds.

Authors:  K J Hellestrand; P J Burnett; J R Milne; R S Bexton; A W Nathan; A J Camm
Journal:  Pacing Clin Electrophysiol       Date:  1983-09       Impact factor: 1.976

5.  Adverse effects of direct current cardioversion on cardiac pacemakers and electrodes Is external cardioversion contraindicated in patients with permanent pacing systems?

Authors:  Christiane Waller; Frank Callies; Heiner Langenfeld
Journal:  Europace       Date:  2004-03       Impact factor: 5.214

6.  Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry?

Authors:  S C Krishnan; C Antzelevitch
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

7.  Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function.

Authors:  V Santinelli; M Arnese; I Oppo; C Matarazzi; S Maione; M Palma; A Giunta
Journal:  Chest       Date:  1993-04       Impact factor: 9.410

8.  Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue.

Authors:  Z Wang; B Fermini; S Nattel
Journal:  J Pharmacol Exp Ther       Date:  1993-11       Impact factor: 4.030

Review 9.  Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.

Authors:  Etienne Aliot; Alessandro Capucci; Harry J Crijns; Andreas Goette; Juan Tamargo
Journal:  Europace       Date:  2010-12-07       Impact factor: 5.214

10.  Electrocardiographic changes in a rare case of flecainide poisoning: a case report.

Authors:  Andrea Rognoni; Marzia Bertolazzi; Marzia Peron; Sergio Macciò; Gemma Ternavasio Cameroni; Angelo Gratarola; Giorgio Rognoni
Journal:  Cases J       Date:  2009-12-03
  10 in total
  1 in total

1.  Flecainide Toxicity Resulting in Pacemaker Latency and Intermittent Failure to Capture.

Authors:  John M Suffredini; Joshua Rutland; Peter Akpunonu; Regan Baum; John Catanzaro; Claude S Elayi
Journal:  Am J Case Rep       Date:  2019-08-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.